Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

Christina U. Lorentz, Erik I. Tucker, Norah G. Verbout, Joseph J. Shatzel, Sven R. Olson, Brandon D. Markway, Michael Wallisch, Martina Ralle, Monica T. Hinds, Owen J. T. McCarty, David Gailani, Jeffrey I. Weitz, András Gruber

Blood (2021) 138 (22): 2173–2184.

https://doi.org/10.1182/blood.2021011725

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase 2 Trial of the Protein C Activator AB002 in End-Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, Christina U Lorentz, Brandon D Markway, Michael Wallisch, Joseph J Shatzel, Andras Gruber, Erik I Tucker

Blood (2021) 138 (Supplement 1): 669.

https://doi.org/10.1182/blood-2021-148208

Published: 2021

Journal Articles

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Christina U Lorentz, PhD, Norah G Verbout, PhD, Joseph J Shatzel, MD, Michael Wallisch, PhD, Brandon D Markway, PhD, Monica T Hinds, PhD, Owen J T McCarty, PhD, David Gailani, MD, Jeffrey I. Weitz, MDFRCPC, Erik I Tucker, PhD, András Gruber, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139948

Published: 2020

Journal Articles

The protein C activator AB002 rapidly interrupts thrombus development in baboons

Erik I. Tucker, Norah G. Verbout, Brandon D. Markway, Michael Wallisch, Christina U. Lorentz, Monica T. Hinds, Joseph J. Shatzel, Leslie A. Pelc, David C. Wood, Owen J. T. McCarty, Enrico Di Cera, András Gruber

Blood (2020) 135 (9): 689–699.

https://doi.org/10.1182/blood.2019002771

Published: 2020

Includes: Supplemental data

Journal Articles

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, PhD, Christina U Lorentz, PhD, Brandon D Markway, PhD, Joseph J Shatzel, MD, Erik I Tucker, PhD, Andras Gruber, MD

Blood (2019) 134 (Supplement_1): 2433.

https://doi.org/10.1182/blood-2019-124999

Published: 2019

NARROW

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

A Phase 2 Trial of the Protein C Activator AB002 in End-Stage Renal Disease Patients on Chronic Hemodialysis

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

The protein C activator AB002 rapidly interrupts thrombus development in baboons

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Email alerts

ASH Publications

American Society of Hematology

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

A Phase 2 Trial of the Protein C Activator AB002 in End-Stage Renal Disease Patients on Chronic Hemodialysis

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

The protein C activator AB002 rapidly interrupts thrombus development in baboons

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only